Premium
Anti‐ Helicobacter pylori therapy in localized gastric mucosa‐associated lymphoid tissue lymphoma: A prospective, nationwide, multicenter study in Japan
Author(s) -
Sugizaki Katsuya,
Tari Akira,
Kitadai Yasuhiko,
Oda Ichiro,
Nakamura Shotaro,
Yoshino Tadashi,
Sugiyama Toshiro
Publication year - 2018
Publication title -
helicobacter
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 79
eISSN - 1523-5378
pISSN - 1083-4389
DOI - 10.1111/hel.12474
Subject(s) - medicine , helicobacter pylori , malt lymphoma , gastroenterology , rabeprazole , lymphoma , mucosa associated lymphoid tissue , rituximab , gastric lymphoma , prospective cohort study , gastrectomy , cancer
Background Helicobacter pylori eradication therapy was approved in Japan for the first‐line, standard treatment of H. pylori ‐positive gastric mucosa‐associated lymphoid tissue ( MALT ) lymphoma. Although several retrospective studies or small‐scale single‐center studies have been reported, a prospective, large‐scale, nationwide, multicenter study has not been reported from Japan. Materials and Methods We conducted a prospective, nationwide, multicenter study to evaluate the clinical efficacy of rabeprazole‐based triple H. pylori eradication therapy for patients with localized gastric MALT lymphoma in practice‐based clinical trial. A total of 108 H. pylori ‐positive patients with stage I/ II 1 gastric MALT lymphoma underwent H. pylori eradication therapy. The primary endpoints were complete remission ( CR ) rate and the rate of transfer to secondary treatment. The secondary endpoints were CR maintenance duration and overall survival ( OS ). Results CR of lymphoma was achieved in 84 of 97 patients (86.6%), during the period 2.0‐44.7 months (median, 5.3 months) after starting H. pylori eradication treatment. CR was maintained in 77 of 81 patients (95.1%) for 0.4‐53.2 months (median, 33.1 months). Secondary treatments (radiotherapy, rituximab, or gastrectomy) for gastric MALT lymphoma were needed in 10 of the 97 patients (10.31%). During follow‐up, OS rate was 96.9% (94/97) and the causes of 3 deaths were not related to lymphoma. Conclusions Rabeprazole‐based H. pylori eradication therapy demonstrated a high CR rate, long CR maintenance, and a good OS for patients with localized gastric MALT lymphoma in this prospective, practice‐based, multicenter study.